Apr 19 |
Spyre Therapeutics files to sell 33.36M shares of common stock for holders
|
Mar 18 |
Spyre Therapeutics climbs 5%, prices $180M private financing
|
Feb 29 |
Spyre Therapeutics GAAP EPS of -$4.05
|
Feb 29 |
Spyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
|
Feb 26 |
Spyre Therapeutics to Participate in the 44th Annual TD Cowen Health Care Conference
|
Feb 8 |
Spyre Therapeutics Announces Three Abstracts Accepted for Presentation at the 19th Annual Congress of the European Crohn's and Colitis Organisation
|
Feb 5 |
Spyre Therapeutics appoints Mark C. Mckenna to its Board
|
Feb 5 |
Spyre Therapeutics Appoints Accomplished Biopharma and IBD Leader Mark C. McKenna, Former Chairman, President, and CEO of Prometheus Biosciences, to its Board of Directors
|
Dec 22 |
Spyre Therapeutics Announces Grants of Inducement Awards
|
Dec 22 |
Spyre Therapeutics to sell 12M shares for holders
|